← Back

C-number: C-26-27-005-X

C-number: C-26-27-005-X-00
Item: #45
Revision: 00
Item Text
45. LICENSE AGREEMENT WITH ASTRAZENECA PHARMACEUTICALS LP FOR THE ASTHMA IMPAIRMENT AND RISK QUESTIONNAIRE (AIRQ®) Approve the License Agreement between AstraZeneca Pharmaceuticals LP and Maricopa County, through its Department of Correctional Health Services (CHS), for the use of the Asthma Impairment and Risk Questionnaire (AIRQ®). The AIRQ® is a validated screening tool recommended in published asthma guidelines to assess asthma control and assist healthcare providers in determining an appropriate treatment plan. The tool is available to CHS at no cost; however, a licensing agreement is required for CHS to formally adopt the AIRQ® as a clinical form and integrate it into the Fusion Electronic Health Record (EHR). The agreement authorizes CHS to use the AIRQ® for its intended clinical purpose and requires CHS to maintain the integrity of the tool, including using the questions as designed without modification. The agreement does not grant AstraZeneca or any other party rights to access or receive CHS patient information. This is a non-financial agreement that becomes effective upon execution and continues indefinitely, subject to the termination provisions outlined in the agreement. (C-26-27-005-X-00)
Attachments (1)

1 item(s) sharing C-number base C-26-27-005-X